// App-Quantinova.ai

: A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Researchers

Presenter

  • Matko Kalac

Principal Investigators

  • Constantine S. Tam

  • Mendel Goldfinger

  • Zhengrui Xiao

  • Francesca Montanari

  • Jennifer A. Kanakry

  • Owen A. O'Connor

  • Enrica Marchi

Medical Centers

  • Montefiore Medical Center, New York, NY

  • Division of Hematology-Oncology; Program for T-Cell Lymphoma Research, University of Virginia, Charlottesville, VA

  • Yale School of Medicine, Greenwich, CT

  • Division of Hematologic Malignancies, Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

  • Program for T-Cell Lymphoma Research, University of Virginia, Charlottesville, VA

  • Peter MacCallum Cancer Centre, MELBOURNE, Australia

  • Ichan School of Medicine at Mount Sinai, New York, NY

  • Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral T-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Azacitidine

  • Vidaza

  • Romidepsin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved